DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DB-1310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DB-1310 overview
The therapeutic candidates are under development for the treatment of metastatic solid tumor, non-small cell lung cancer, castration resistant prostate cancer and head and neck squamous cell cancer and HER2 positive breast cancer. The drug candidate is administered through intravenous route as injection. They are antibody drug conjugates (ADCs) comprised of a humanized anti-HER3 IgG1 monoclonal antibody, covalently linked to a proprietary DNA topoisomerase I inhibitor (P1021) via a maleimide tetrapeptide-based cleavable linker and is being developed based on duality immune toxin antibody conjugate platform.
Duality Biologics (Shanghai) overview
Duality Biologics (Shanghai) is a company focusing on the development, commercialization and discovery of new modality biologics to provide solutions. The company is headquartered in Shanghai, China.
For a complete picture of DB-1310’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.